TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study

Yuki Katayama, MD; Tadaaki Yamada, MD, PhD; Kenji Morimoto, MD, PhD; Hiroyuki Fujii, MD; Satomi Morita, MD; Keiko Tanimura, MD, PhD; Takayuki Takeda, MD, PhD; Asuka Okada, MD, PhD; Shinsuke Shiotsu, MD, PhD; Yusuke Chihara, MD, PhD; Osamu Hiranuma, MD; Takahiro Yamada, MD, PhD; Takahiro Ota, MD, PhD; Taishi Harada, MD; Isao Hasegawa, MD, PhD; Akihiro Yoshimura, MD, PhD; Masahiro Iwasaku, MD, PhD; Shinsaku Tokuda, MD, PhD; Young Hak Kim, MD, PhD; Koichi Takayama, MD, PhD

JTO Clinical and Research Reports (Apr 2023)

TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study

Yuki Katayama, MD,
Tadaaki Yamada, MD, PhD,
Kenji Morimoto, MD, PhD,
Hiroyuki Fujii, MD,
Satomi Morita, MD,
Keiko Tanimura, MD, PhD,
Takayuki Takeda, MD, PhD,
Asuka Okada, MD, PhD,
Shinsuke Shiotsu, MD, PhD,
Yusuke Chihara, MD, PhD,
Osamu Hiranuma, MD,
Takahiro Yamada, MD, PhD,
Takahiro Ota, MD, PhD,
Taishi Harada, MD,
Isao Hasegawa, MD, PhD,
Akihiro Yoshimura, MD, PhD,
Masahiro Iwasaku, MD, PhD,
Shinsaku Tokuda, MD, PhD,
Young Hak Kim, MD, PhD,
Koichi Takayama, MD, PhD

Affiliations

Yuki Katayama, MD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Tadaaki Yamada, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Corresponding author. Address for correspondence: Tadaaki Yamada, MD, PhD, Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan.
Kenji Morimoto, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Hiroyuki Fujii, MD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Satomi Morita, MD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Keiko Tanimura, MD, PhD: Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan
Takayuki Takeda, MD, PhD: Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan
Asuka Okada, MD, PhD: Department of Respiratory Medicine, Saiseikai Suita Hospital, Osaka, Japan
Shinsuke Shiotsu, MD, PhD: Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan
Yusuke Chihara, MD, PhD: Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Kyoto, Japan
Osamu Hiranuma, MD: Department of Respiratory Medicine, Otsu City Hospital, Shiga, Japan
Takahiro Yamada, MD, PhD: Department of Respiratory Medicine, Matsushita Memorial Hospital, Osaka, Japan
Takahiro Ota, MD, PhD: Department of Respiratory Medicine, Kyoto city Hospital, Kyoto, Japan
Taishi Harada, MD: Department of Medical Oncology, Fukuchiyama City Hospital, Kyoto, Japan
Isao Hasegawa, MD, PhD: Department of Respiratory Medicine, Saiseikai Shigaken Hospital, Shiga, Japan
Akihiro Yoshimura, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Masahiro Iwasaku, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Shinsaku Tokuda, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Young Hak Kim, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Koichi Takayama, MD, PhD: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

Journal volume & issue: Vol. 4, no. 4
p. 100494

Abstract

Read online

Introduction: Lung adenocarcinoma with negative TTF-1 expression is believed to be a poor prognostic factor for certain systemic treatments. Nevertheless, the impact of TTF-1 expression on combined chemoimmunotherapy remains unclear. We aimed to investigate the relationship between tumor TTF-1 expression and the efficacy of combined chemoimmunotherapy in patients with advanced lung adenocarcinoma. Methods: This multicenter prospective observational study included 58 patients with advanced lung adenocarcinoma treated with combined chemoimmunotherapy across 10 institutions in Japan. The expression of TTF-1 in pretreatment tumors was determined using immunohistochemistry. Results: The objective response rate of combined chemoimmunotherapy was significantly higher in TTF-1–positive groups than in TTF-1–negative groups (p = 0.02). The median progression-free survival (PFS) and overall survival were significantly longer in TTF-1–positive groups than in TTF-1–negative groups (10.9 versus 5.0 mo; p = 0.01). Multivariate analysis revealed that TTF-1 expression was an independent favorable prognostic factor for PFS. Moreover, TTF-1 expression in patients with lung adenocarcinoma is significantly associated with programmed death-ligand 1 expression (p = 0.003). The TTF-1–positive group with programmed death-ligand 1 tumor proportion score greater than or equal to 50% had a significantly longer PFS than the other groups (p = 0.02). Conclusions: TTF-1 positivity is associated with better clinical outcomes in patients with advanced lung adenocarcinoma treated with combined chemoimmunotherapy.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords